ClinicalTrials.gg

Program

KRAS Mutant Inhibitor ALTA3263

Its studies are mostly in Neoplasms, led by Alterome Therapeutics.

Furthest: phase 1, since Feb 14, 20251 company-led study, 1 open or runningNext primary completion: May 2029 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Alterome Therapeutics11 open or runningphase 1since Feb 14, 2025Feb 14, 2025May 2029phase 1 · NCT06835569

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 14, 2025First study: phase 1 study in NeoplasmsFirst studyNCT06835569 · 448 planned · United States

Ahead

  1. May 2029Primary completion: phase 1 study in NeoplasmsNCT06835569

TargetBeta

KRAS →read by rule
“An orally bioavailable non-covalent dual ON/OFF state inhibitor of multiple oncogenic KRAS mutant forms, including KRAS G12V, G12D and G12C, ”NCIt, by rule

Other programs on KRAS

ProgramCompanyFurthest phaseStudies
sotorasibruleAmgenphase 328
adagrasibruleBristol-Myers Squibbphase 316
olomorasibEli Lillyphase 316
divarasibHoffmann-La Rochephase 313
KRAS G12D Inhibitor VS-7375ruleGenfleet Therapeutics (Shanghai)phase 312
glecirasibruleAllist Pharmaceuticalsphase 312
calderasibMerckphase 312
daraxonrasibruleRevolution Medicinesphase 310
garsorasibruleInventisBiophase 38
KRAS G12D Inhibitor HRS-4642Jiangsu HengRui Medicinephase 37
zoldonrasibruleRevolution Medicinesphase 36
HRS-7058Jiangsu HengRui Medicinephase 36

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06835569Neoplasms · United States1RecruitingMay 2029448

How it is read

Names in the registry

  • “ALTA3263”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.